Skip to content
Review Open access

Tumor-intrinsic execution of interferon-γ-associated immunity in bladder cancer: checkpoints in signaling, recruitment, and recognition

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 47 references
Medicine

TL;DR

This Mini Review examines tumor-intrinsic IFN-γ-associated immunity at three functional checkpoints: proximal IFN-γ sensing and signal transduction, chemokine-mediated effector-cell recruitment, and antigen-presentation-dependent tumor recognition.

Abstract

Interferon-γ (IFN-γ) is a central mediator of antitumor immunity in bladder cancer, but an IFN-γ-rich tumor microenvironment does not necessarily translate into tumor control. Tissue-level inflammatory signatures capture overall immune activity and cannot determine whether malignant urothelial cells remain responsive to immune-derived IFN-γ or preserve the downstream functions required for immune elimination. This Mini Review examines tumor-intrinsic IFN-γ-associated immunity at three functional checkpoints: proximal IFN-γ sensing and signal transduction, chemokine-mediated effector-cell recruitment, and antigen-presentation-dependent tumor recognition. Bladder cancer models show that IFNGR–JAK–STAT1 responsiveness can be lost or attenuated, while separate tumor-intrinsic mechanisms can restrict CXCL9/CXCL10-dependent T-cell recruitment without a demonstrated proximal signaling defect. Antigen presentation forms a further checkpoint, with HLA-I and antigen-processing machinery altered through transcriptional, treatment-associated, and post-translational mechanisms. These mechanisms do not constitute a single linear IFN-γ resistance pathway. They instead mark distinct points at which inflammatory pressure can become uncoupled from tumor elimination. IFN-γ-responsive programs are also shaped by treatment context and signaling duration, as illustrated by CIITA/MHC-II biology and prolonged interferon signaling. Resolving these processes at malignant-cell, spatial, and longitudinal levels may improve the interpretation of BCG and checkpoint-blockade resistance and support more selective combination strategies.

Read PDF

Similar papers

Open access Nov 2026

IFNAR1 stabilization sustains CD8+ T cell persistence in IFN-high colorectal cancer liver metastases

Colorectal cancer liver metastases (CRC-LMs) are associated with poor survival and frequently resist immunotherapy, yet the mechanisms underlying this immune refractoriness remain incompletely defined. Here, we identify a tumor-intrinsic type I interferon (IFN-I)–high state in CRC-LMs associated with loss of the IFN-α/...

A. Castiglioni, A. Monestiroli, G. Delfanti et al. · 0 citations
Review Sep 2026

The cGAS-STING signaling in hepatocellular carcinoma: A spatiotemporally gated immune switch linking pro-tumorigenic immune evasion and anti-tumor therapeutic response.

Hepatocellular carcinoma (HCC) arises from chronic inflammation and immune tolerance, posing substantial challenges for immunotherapy. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling is a central immunological hub linking innate immune sensing to adaptive immune responses in tumors. In...

Yuan Chen, Yu-Hong An, Chao-Qun Wang et al. · 0 citations
Open access Oct 2026

Inflammatory signaling drives SQSTM1-dependent suppression of interferon-γ–induced MHC class I surface expression

Findings identify post-translational MHC-I trafficking as a previously underappreciated regulatory layer linking inflammatory signaling to the canonical IFN-γ–MHC-I axis and reveal an SQSTM1-dependent mechanism controlling MHC-I surface availability under immune-inflamed tumor conditions.

Shohei Yamashita, Hiroe Shuto, Aiko Hirayama et al. · 0 citations
Review Open access Oct 2026

Beyond immune surveillance: IFN-γ and PD-L1 as shapers of tumor plasticity in Non-Small Cell Lung Cancer (NSCLC)

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have transformed the treatment of Non-Small Cell Lung Cancer (NSCLC), yet durable responses remain limited to a minority of patients. Tumor plasticity is increasingly recognized as a determinant of immunotherapy resistance, although the tumor-intrinsic c...

Stefania Angelicola, M. Frascino, I. Chillico et al. · 0 citations
Review Oct 2026

Decoding Innate T Cell Functionality in Tumor Immunity and Therapeutic Response

Innate T cells, including invariant natural killer T (iNKT) cells, mucosal-associated invariant T (MAIT) cells, and γδ T cells, bridge innate and adaptive immunity through rapid responses to nonpeptide antigens, metabolites, and stress-associated signals. In cancer, these populations can promote tumor surveillance thro...

Yu-Ning Chen, Annabel S. Zhao, Catherine Zhang et al. · 0 citations
Open access Oct 2026

MHC-I downregulation is associated with immune-evasion in breast cancers with heterogeneous activation of epithelial-mesenchymal plasticity

Cancer cell-intrinsic epithelial-mesenchymal plasticity (EMP) drives carcinoma progression through increased intratumoral heterogeneity and an immunosuppressive tumor microenvironment (TME). Specifically, EMP activation in murine mammary carcinomas results in exclusion of CD8+ T-cells and recruitment of immunosuppressi...

Kimaya M. Bakhle, Andreas Stephanou, Sarthak Sahoo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.